Thomas F. Ryan, Jr. net worth and biography

Thomas Ryan, Jr. Biography and Net Worth

Director of Repligen

Thomas F. Ryan Jr. has served as a director of Repligen since September 2003. Mr. Ryan is currently an investor in various private companies. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a director for the New York State Independent System Operator and a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.

What is Thomas F. Ryan, Jr.'s net worth?: The estimated net worth of Thomas F. Ryan, Jr. is at least $408,186.24 as of March 3rd, 2021. Mr. Ryan, Jr. owns 2,464 shares of Repligen stock worth more than $408,186 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Ryan, Jr. may own. Learn More about Thomas F. Ryan, Jr.'s net worth.
How do I contact Thomas F. Ryan, Jr.?: The corporate mailing address for Mr. Ryan, Jr. and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Thomas F. Ryan, Jr.'s contact information.
Has Thomas F. Ryan, Jr. been buying or selling shares of Repligen?: Thomas F. Ryan, Jr. has not been actively trading shares of Repligen during the past quarter. Most recently, Thomas F. Ryan, Jr. sold 2,000 shares of the business's stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $198.03, for a transaction totalling $396,060.00. Learn More on Thomas F. Ryan, Jr.'s trading history.
Who are Repligen's active insiders?: Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (CEO), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?: In the last year, Repligen insiders bought shares 2 times. They purchased a total of 1,000 shares worth more than $158,665.00. In the last year, insiders at the biotechnology company sold shares 6 times. They sold a total of 30,235 shares worth more than $5,742,533.77. The most recent insider tranaction occured on March, 11th when VP Ralf Kuriyel sold 3,517 shares worth more than $681,348.41. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.
Information on this page was last updated on 3/11/2024.

Thomas F. Ryan, Jr. Insider Trading History at Repligen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2022	Sell	2,000	$198.03	$396,060.00
11/4/2021	Sell	1,000	$288.00	$288,000.00
8/4/2021	Sell	780	$250.50	$195,390.00
3/3/2021	Sell	1,000	$205.00	$205,000.00	2,464
11/11/2020	Sell	934	$187.73	$175,339.82	2,398
7/31/2020	Sell	3,095	$151.90	$470,130.50	4,559
3/4/2020	Sell	4,796	$88.82	$425,980.72	1,923
11/5/2018	Sell	1,763	$65.75	$115,917.25	3,225
8/22/2018	Sell	2,366	$51.44	$121,707.04	4,988
6/6/2018	Sell	1,932	$44.31	$85,606.92	7,354
3/8/2018	Sell	4,696	$36.16	$169,807.36	9,700
3/20/2017	Sell	4,000	$34.83	$139,320.00	12,594
9/14/2016	Sell	2,700	$32.58	$87,966.00	9,394
6/30/2016	Sell	5,000	$26.60	$133,000.00	12,094
6/28/2016	Sell	10,000	$24.59	$245,900.00	27,094
5/8/2015	Sell	20,000	$37.19	$743,800.00
3/19/2015	Sell	10,000	$32.62	$326,200.00
11/13/2014	Sell	10,000	$23.81	$238,100.00
6/27/2014	Sell	10,000	$22.41	$224,100.00
6/24/2014	Sell	10,000	$21.78	$217,800.00
5/17/2013	Sell	21,000	$8.97	$188,370.00
5/15/2013	Sell	86,039	$9.01	$775,211.39

Thomas F. Ryan, Jr. Buying and Selling Activity at Repligen

Repligen Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $166.58

$165.04

$168.46

50 Day Range

MA: $185.05

$157.06

$208.42

2 Week Range

Now: $166.58

$110.45

$211.13

Volume

341,269 shs

Average Volume

532,608 shs

Market Capitalization

$9.30 billion

P/E Ratio

231.36

Dividend Yield

N/A

Beta

1.02

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy